DK2504354T3 - Citrullinerede virale peptider og anvendelser deraf - Google Patents
Citrullinerede virale peptider og anvendelser deraf Download PDFInfo
- Publication number
- DK2504354T3 DK2504354T3 DK10822880.0T DK10822880T DK2504354T3 DK 2504354 T3 DK2504354 T3 DK 2504354T3 DK 10822880 T DK10822880 T DK 10822880T DK 2504354 T3 DK2504354 T3 DK 2504354T3
- Authority
- DK
- Denmark
- Prior art keywords
- cit
- peptide
- rheumatoid arthritis
- specific
- antibodies
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 143
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 40
- 230000003612 virological effect Effects 0.000 title claims description 5
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical group NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 99
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 21
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 19
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 16
- 208000023275 Autoimmune disease Diseases 0.000 claims description 13
- 235000013477 citrulline Nutrition 0.000 claims description 11
- 150000001413 amino acids Chemical group 0.000 claims description 9
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 8
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 229940000635 beta-alanine Drugs 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 8
- 229960002173 citrulline Drugs 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 6
- 238000010324 immunological assay Methods 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 241000207199 Citrus Species 0.000 claims 2
- 235000020971 citrus fruits Nutrition 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 70
- 238000009448 modified atmosphere packaging Methods 0.000 description 44
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 42
- HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 description 31
- 239000000427 antigen Substances 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 239000013256 coordination polymer Substances 0.000 description 21
- 235000009697 arginine Nutrition 0.000 description 20
- 108010015792 glycyllysine Proteins 0.000 description 20
- 239000004475 Arginine Substances 0.000 description 19
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 19
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- HQIZDMIGUJOSNI-IUCAKERBSA-N Arg-Gly-Arg Chemical compound N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQIZDMIGUJOSNI-IUCAKERBSA-N 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 14
- 206010003246 arthritis Diseases 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 12
- 108700003816 citrullinated- EBNA-2 protein (338-358) Proteins 0.000 description 12
- 101150113929 EBNA2 gene Proteins 0.000 description 10
- 101710122228 Epstein-Barr nuclear antigen 2 Proteins 0.000 description 10
- 241000219061 Rheum Species 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 8
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- JLXVRFDTDUGQEE-YFKPBYRVSA-N Gly-Arg Chemical compound NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N JLXVRFDTDUGQEE-YFKPBYRVSA-N 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 102100025721 Cytosolic carboxypeptidase 2 Human genes 0.000 description 5
- 101000932634 Homo sapiens Cytosolic carboxypeptidase 2 Proteins 0.000 description 5
- 101001090860 Homo sapiens Myeloblastin Proteins 0.000 description 5
- 101001033011 Mus musculus Granzyme C Proteins 0.000 description 5
- 102100034681 Myeloblastin Human genes 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- GLGAUBPACOBAMV-DOFZRALJSA-N arachidonylcyclopropylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NC1CC1 GLGAUBPACOBAMV-DOFZRALJSA-N 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 239000013060 biological fluid Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 108010061103 cyclic citrullinated peptide Proteins 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 102100028314 Filaggrin Human genes 0.000 description 3
- 101710088660 Filaggrin Proteins 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 description 3
- 206010042953 Systemic sclerosis Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 201000003278 cryoglobulinemia Diseases 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 201000006747 infectious mononucleosis Diseases 0.000 description 3
- 235000019837 monoammonium phosphate Nutrition 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 102100025707 Cytosolic carboxypeptidase 3 Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000932588 Homo sapiens Cytosolic carboxypeptidase 3 Proteins 0.000 description 2
- 101001033009 Mus musculus Granzyme E Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 108091006007 citrullinated proteins Proteins 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229940030980 inova Drugs 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 238000005497 microtitration Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- VXLBDJWTONZHJN-YUMQZZPRSA-N Asn-His-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)N)N VXLBDJWTONZHJN-YUMQZZPRSA-N 0.000 description 1
- OAMLVOVXNKILLQ-BQBZGAKWSA-N Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O OAMLVOVXNKILLQ-BQBZGAKWSA-N 0.000 description 1
- BKOIIURTQAJHAT-GUBZILKMSA-N Asp-Pro-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 BKOIIURTQAJHAT-GUBZILKMSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101710155594 Coiled-coil domain-containing protein 115 Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100035027 Cytosolic carboxypeptidase 1 Human genes 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- UFPXDFOYHVEIPI-BYPYZUCNSA-N Gly-Gly-Asp Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O UFPXDFOYHVEIPI-BYPYZUCNSA-N 0.000 description 1
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 1
- OOCFXNOVSLSHAB-IUCAKERBSA-N Gly-Pro-Pro Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OOCFXNOVSLSHAB-IUCAKERBSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- LGSANCBHSMDFDY-GARJFASQSA-N Pro-Glu-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O LGSANCBHSMDFDY-GARJFASQSA-N 0.000 description 1
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 1
- TYMBHHITTMGGPI-NAKRPEOUSA-N Pro-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1 TYMBHHITTMGGPI-NAKRPEOUSA-N 0.000 description 1
- SXJOPONICMGFCR-DCAQKATOSA-N Pro-Ser-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O SXJOPONICMGFCR-DCAQKATOSA-N 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- CDEZPHVWBQFJQQ-NKKJXINNSA-N Trp-Trp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CNC5=CC=CC=C54)N)C(=O)O CDEZPHVWBQFJQQ-NKKJXINNSA-N 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003456 anti-perinuclear Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 150000001484 arginines Chemical class 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 108700008737 citrullinated- EBNA 1 protein (35-58) Proteins 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010020432 prolyl-prolylisoleucine Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- OIWCYIUQAVBPGV-DAQGAKHBSA-N {1-O-hexadecanoyl-2-O-[(Z)-octadec-9-enoyl]-sn-glycero-3-phospho}serine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC OIWCYIUQAVBPGV-DAQGAKHBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
- CITRULLINEREDE VIRALE PEPTIDER OG ANVENDELSER DERAF1. Antigent effektivt peptid, som fra aminoenden til carboxylenden består af aminosyresekvensen: G Q S Xt G Q S X2 G X3 G X4 G X5 G X6 G X7 G K G (aa 19 til aa 39 ifølge SEQ ID NO: 1), hvor aminosyrerne X1-X7 er uafhængigt valgt blandt en argininrest og en citrullinrest, og mindst én af X1-X7 er en citrullinrest, eller et funktionelt fragment deraf, hvilket antigent effektive peptid og fragment deraf er i stand til specifikt at binde reumatoid arthritis-specifikke antistoffer og/eller reumatoid arthritis-specifikke T-celler.
- 2. Peptid ifølge krav 1, som består af aminosyresekvensen G Q S Cit G Q S Cit G X3 G Cit G X5 G Χβ G X7 G K G (SEQ ID NO: 27), hvor aminosyrerne X3-X7 er uafhængigt valgt blandt en argininrest og en citrullinrest.
- 3. Peptid ifølge krav 1 eller 2, som består af sekvensen valgt fra gruppen bestående af: GQSRGQSCitGRGRGRGRGRGKG (SEQ ID NO: 4), G Q S R G Q S R G RGCitGRGRGRGKG (SEQ ID NO: 6), G Q S R G Q S Cit G R G Cit G R G R G R G K G (SEQ ID NO: 12), G Q S Cit G Q S Cit G R G Cit G R G R G R G K G (SEQ ID NO: 22) eller G Q S Cit G Q S Cit G Cit G Cit G Cit G Cit G Cit G K G (SEQ ID NO: 2), hvor Cit er en citrullinrest, et funktionelt fragment deraf, hvilket fragment er i stand til specifikt at binde reumatoid arthritis-specifikke antistoffer og/eller reumatoid arthritis-specifikke T-celler.
- 4. Peptid ifølge et hvilket som helst af de foregående krav, som har lineær form.
- 5. Multimert forgrenet peptid, som består af flere peptider ifølge et hvilket som helst af kravene 1-3.
- 6. Multimert forgrenet peptid ifølge krav 5, som omfatter fire identiske eksemplarer af peptidet ifølge krav 1 -3.
- 7. Multimert forgrenet peptid ifølge krav 6, som er (G Q S Cit G Q S Cit G Cit G Cit G Cit G Cit G Cit G K G)4 K2 K beta-alanin:hvor Cit er en citrullinrest.
- 8. Fremgangsmåde til diagnosticering af reumatoid arthritis hos et individ, hvilken fremgangsmåde omfatter trinet til påvisning af antistoffer, som er specifikke for den autoimmune sygdom, i en biologisk prøve, som er fremskaffet fra individet, ved - omsætning under passende betingelser af den biologiske prøve med mindst ét peptid eller multimert forgrenet peptid ifølge et hvilket som helst af kravene 1-7 for at frembringe et kompleks; - påvisning af komplekset.
- 9. Fremgangsmåde ifølge krav 8, hvor den biologiske prøve omsættes med mindst ét peptid eller multimert forgrenet peptid ifølge et hvilket som helst af kravene 1-7 og et multimert forgrenet peptid, som omfatter sekvensen (G G D N Fl G Cit G Cit G Cit G Cit G Cit G G G Cit P G A P G)4 K2 K beta-alanin:hvor: Cit = citrullin, eller et funktionelt fragment deraf, hvilket fragment er i stand til specifikt at binde reumatoid arthritis-specifikke antistoffer og/eller reumatoid arthritis-specifikke T-celler.
- 10. Fremgangsmåde ifølge krav 9, hvor den biologiske prøve omsættes med det multimere forgrenede peptid, som består af sekvensen (G Q S Cit G Q S Cit G Cit G Cit G Cit G Cit G Cit G K G)4 K2 K beta-alanin:hvor Cit = citrullin, eller et funktionelt fragment deraf, hvilket fragment er i stand til specifikt at binde reumatoid arthritis-specifikke antistoffer og/eller reumatoid arthritis-specifikke T-celler, og det multimere forgrenede peptid, som omfatter sekvensen (G G D N Fl G Cit G Cit G Cit G Cit G Cit G G G Cit P G A P G)4 K2 K beta-alanin:hvor: Cit = citrullin, eller et funktionelt fragment deraf, hvilket fragment er i stand til specifikt at binde reumatoid arthritis-specifikke antistoffer og/eller reumatoid arthritis-specifikke T-celler.
- 11. Fremgangsmåde ifølge et hvilket som helst af kravene 8-10, hvilken fremgangsmåde er et immunologisk assay.
- 12. Kit til diagnosticering af reumatoid arthritis, hvilket kit omfatter mindst ét peptid eller multimert forgrenet peptid ifølge et hvilket som helst af kravene 1-7 eller et funktionelt fragment deraf, hvilket fragment er i stand til specifikt at binde reumatoid arthritis-specifikke antistoffer og/eller reumatoid arthritis-specifikke T-celler.
- 13. Kit ifølge krav 12, hvilket kit endvidere omfatter det multimere forgrenede peptid, som omfatter sekvensen (G G D N H G Cit G Cit G Cit G Cit G Cit G G G Cit P G A P G)4 K2 K beta-alanin:hvor: Cit = citrullin, eller et funktionelt fragment deraf, hvilket fragment er i stand til specifikt at binde reumatoid arthritis-specifikke antistoffer og/eller reumatoid arthritis-specifikke T-celler.
- 14. Farmaceutisk sammensætning, som omfatter en farmaceutisk acceptabel og effektiv mængde af peptidet eller det multimere forgrenede peptid ifølge et hvilket som helst af kravene 1-7 eller et funktionelt fragment deraf, hvilket fragment er i stand til specifikt at binde reumatoid arthritis-specifikke antistoffer og/eller reumatoid arthritis-specifikke T-celler.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09176776A EP2325195A1 (en) | 2009-11-23 | 2009-11-23 | Viral citrullinated peptides and uses thereof |
| PCT/IB2010/055347 WO2011061720A2 (en) | 2009-11-23 | 2010-11-22 | Viral citrullinated peptides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2504354T3 true DK2504354T3 (da) | 2015-05-11 |
Family
ID=41611932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10822880.0T DK2504354T3 (da) | 2009-11-23 | 2010-11-22 | Citrullinerede virale peptider og anvendelser deraf |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8900880B2 (da) |
| EP (2) | EP2325195A1 (da) |
| CN (1) | CN102666569A (da) |
| AU (1) | AU2010320523B2 (da) |
| BR (1) | BR112012012190A2 (da) |
| CA (1) | CA2781560A1 (da) |
| DK (1) | DK2504354T3 (da) |
| EA (1) | EA022520B1 (da) |
| ES (1) | ES2535530T3 (da) |
| IL (1) | IL219798A0 (da) |
| PL (1) | PL2504354T3 (da) |
| WO (1) | WO2011061720A2 (da) |
| ZA (1) | ZA201203730B (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2527841A1 (en) | 2011-05-25 | 2012-11-28 | Toscana Biomarkers S.r.l. | Methods for the diagnosis of rheumatoid arthritis |
| CN106279361A (zh) | 2015-06-26 | 2017-01-04 | 韩震 | 一种多肽化合物及其制备方法与应用 |
| CN108196073B (zh) * | 2018-03-13 | 2019-09-13 | 江苏浩欧博生物医药股份有限公司 | 一种测定抗环瓜氨酸肽抗体的试剂盒及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2752842B1 (fr) | 1996-08-30 | 1998-11-06 | Biomerieux Sa | Antigenes derives des filaggrines et leur utilisation pour le diagnostic de la polyarthrite rhumatoide |
| NL1004539C2 (nl) | 1996-11-15 | 1998-05-20 | Stichting Tech Wetenschapp | Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen. |
| US7273613B1 (en) * | 1997-01-13 | 2007-09-25 | The Board of Regents, The University of Oklahoma | Diagnostics and therapy of Epstein-Barr virus in autoimmune disorders |
| JP2002512939A (ja) | 1997-11-28 | 2002-05-08 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 診断および治療のためのツールとしての、リューマチ性関節炎の血清により認識されるシトルリン含有合成ペプチド |
| FR2795735B1 (fr) | 1999-07-01 | 2001-09-07 | Univ Toulouse | Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumatoide |
| WO2001046222A2 (en) | 1999-12-21 | 2001-06-28 | Innogenetics N.V. | Peptides designed for the diagnosis and treatment of rheumatoid arthritis |
| NL1019540C2 (nl) | 2001-12-11 | 2003-07-01 | Stichting Tech Wetenschapp | Werkwijze voor het detecteren van auto-antilichamen van patienten die lijden aan reumatoïde artritis, peptide en assaykit. |
| ITTO20030246A1 (it) | 2003-03-31 | 2004-10-01 | Univ Pisa | Nuovi peptidi sintetici citrullinati e loro usi. |
| ATE401338T1 (de) | 2004-11-04 | 2008-08-15 | Biomerieux Sa | Von fibrin abgeleitete citrullinpeptide, die durch für rheumatoide arthritis spezifische autoantikörper erkannt werden, und deren verwendung |
| FI20050814A0 (fi) | 2005-08-11 | 2005-08-11 | Procollagen Oy | Menetelmä nivelreumassa muodostuvien kollageeniautovasta-aineiden havaitsemiseksi |
| US20070148704A1 (en) | 2005-10-06 | 2007-06-28 | Ursula Klause | Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis |
| ES2307421B1 (es) | 2007-04-30 | 2009-09-28 | Consejo Superiorde Investigaciones Cientificas (Csic) | Polipeptido quimerico fibrina-filagrina citruinado capaz de detectar los anticuerpos generados en la artritis reumatoide. |
| US20110165606A1 (en) | 2007-06-15 | 2011-07-07 | Tutturen Astrid E V | Methods for modifying, isolating, detecting, visualizing, and quantifying citrullinated and/or homocitrullinated peptides, polypeptides and proteins |
| US8323656B2 (en) | 2007-06-25 | 2012-12-04 | Yijun Xu | Antigen determinant of rheumatoid arthritis-specific autoantibody and use thereof |
-
2009
- 2009-11-23 EP EP09176776A patent/EP2325195A1/en not_active Withdrawn
-
2010
- 2010-11-22 WO PCT/IB2010/055347 patent/WO2011061720A2/en not_active Ceased
- 2010-11-22 DK DK10822880.0T patent/DK2504354T3/da active
- 2010-11-22 US US13/510,091 patent/US8900880B2/en not_active Expired - Fee Related
- 2010-11-22 AU AU2010320523A patent/AU2010320523B2/en not_active Ceased
- 2010-11-22 EA EA201290384A patent/EA022520B1/ru not_active IP Right Cessation
- 2010-11-22 CN CN2010800529602A patent/CN102666569A/zh active Pending
- 2010-11-22 CA CA2781560A patent/CA2781560A1/en not_active Abandoned
- 2010-11-22 EP EP10822880.0A patent/EP2504354B1/en not_active Not-in-force
- 2010-11-22 PL PL10822880T patent/PL2504354T3/pl unknown
- 2010-11-22 ES ES10822880.0T patent/ES2535530T3/es active Active
- 2010-11-22 BR BR112012012190A patent/BR112012012190A2/pt not_active IP Right Cessation
-
2012
- 2012-05-15 IL IL219798A patent/IL219798A0/en unknown
- 2012-05-22 ZA ZA2012/03730A patent/ZA201203730B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011061720A3 (en) | 2011-08-11 |
| EP2504354B1 (en) | 2015-02-11 |
| AU2010320523A1 (en) | 2012-06-21 |
| BR112012012190A2 (pt) | 2017-01-10 |
| CA2781560A1 (en) | 2011-05-26 |
| US20130017560A1 (en) | 2013-01-17 |
| ES2535530T3 (es) | 2015-05-12 |
| EP2504354A2 (en) | 2012-10-03 |
| IL219798A0 (en) | 2012-07-31 |
| EP2325195A1 (en) | 2011-05-25 |
| US8900880B2 (en) | 2014-12-02 |
| AU2010320523B2 (en) | 2014-06-12 |
| WO2011061720A2 (en) | 2011-05-26 |
| PL2504354T3 (pl) | 2015-10-30 |
| ZA201203730B (en) | 2013-02-27 |
| EA201290384A1 (ru) | 2012-12-28 |
| EA022520B1 (ru) | 2016-01-29 |
| CN102666569A (zh) | 2012-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0420913B1 (en) | Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same | |
| DK2588495T3 (da) | Histoncitrullinerede peptider og anvendelser deraf | |
| EP0747481B1 (en) | Epstein-Barr virus peptides and antibodies against these peptides | |
| DK2504354T3 (da) | Citrullinerede virale peptider og anvendelser deraf | |
| US20140106381A1 (en) | Method for the diagnosis of rheumatoid arthritis | |
| EP2592419A1 (en) | Method for detection of infection with human cytomegalovirus | |
| CA2034611C (en) | Synthetic peptide compositions with immunoreactivities to antibodies to htlv | |
| AU746231B2 (en) | Reagent for detecting and monitoring viral infections | |
| KR100467395B1 (ko) | HIV-1항원p24및gp41의제조방법 | |
| EP0362915A2 (en) | Synthetic polypeptides immunochemically reactive with HIV-antibodies | |
| HK1001164B (en) | Epstein-barr virus peptides and antibodies against these peptides |